Sign inCreate account

Report workspace tools

NCT01975779COMPLETEDanonymous

Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Sponsor

Source record

H. Lundbeck A/S

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Lu AE58054

Indication / condition

AI-normalized

Healthy

Intervention

Source record

Cohort A1: Lu AE58054 or placebo, Cohort A2: Lu AE58054 or placebo, Cohort B1: Lu AE58054

Source & freshness

Source record

NCT ID

NCT01975779

Original source

ClinicalTrials.gov

Source last updated

Nov 05, 2013

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01975779

Title

Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Sponsor

H. Lundbeck A/S

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

Healthy

Modality normalized

small molecule

Target raw

Lu AE58054

Target normalized

Lu AE58054

Interventions

Cohort A1: Lu AE58054 or placebo, Cohort A2: Lu AE58054 or placebo, Cohort B1: Lu AE58054

Public preview

Source record

This clinical trial, sponsored by H. Lundbeck A/S, evaluated the safety, tolerability, and pharmacokinetics of Lu AE58054 in healthy young Japanese and Caucasian men. The study was designed as a randomized, double-blind, placebo-controlled trial with a total enrollment of 42 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01975779

Status

COMPLETED

Phase

PHASE1

Sponsor

H. Lundbeck A/S

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by H. Lundbeck A/S, evaluated the safety, tolerability, and pharmacokinetics of Lu AE58054 in healthy young Japanese and Caucasian men. The study was designed as a randomized, double-blind, placebo-controlled trial with a total enrollment of 42 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 05, 2013
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01975779

Indication

Healthy

Modality

small molecule

Target

Lu AE58054

Intervention

Cohort A1: Lu AE58054 or placebo, Cohort A2: Lu AE58054 or placebo, Cohort B1: Lu AE58054

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.